Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
Search Article 
Advanced search 
  Users Online: 2152 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

Table of Contents
Year : 2011  |  Volume : 15  |  Issue : 5  |  Page : 67-68

Diabetic cardiac autonomic neuropathy in well-controlled diabetics within 1 year of diagnosis

Department of Medicine, Jinnah-Allama Iqbal Institute of Diabetes and Endocrinology, Lahore, Pakistan

Date of Web Publication20-Jul-2011

Correspondence Address:
Ali Jawa
Jinnah-Allama Iqbal Institute of Diabetes and Endocrinology, Lahore-54550
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/2230-8210.83045

Rights and Permissions

How to cite this article:
Jawa A, Bokhari R, Jawad A, Akram J. Diabetic cardiac autonomic neuropathy in well-controlled diabetics within 1 year of diagnosis. Indian J Endocr Metab 2011;15, Suppl S1:67-8

How to cite this URL:
Jawa A, Bokhari R, Jawad A, Akram J. Diabetic cardiac autonomic neuropathy in well-controlled diabetics within 1 year of diagnosis. Indian J Endocr Metab [serial online] 2011 [cited 2021 Feb 28];15, Suppl S1:67-8. Available from: https://www.ijem.in/text.asp?2011/15/5/67/83045


Diabetic Cardiac Autonomic Neuropathy (DCAN) is associated with high risk of cardiovascular morbidity and mortality. [1] Several methods have been devised to assess cardiac autonomic neuropathy such as measurement of resting heart rate (HR), HR variability, etc. Reduced HR variability has been associated with increased cardiac events in diabetic subjects. [2] Portable ANSiscope is a device that noninvasively measures the parasympathetic/sympathetic nervous system imbalance in an office setting. The ANSiscope computes a percentage of dysautonomia from a recording of 571 RR intervals termed ANS index.

Based on scoring described by Bellavere et al., [3] five risk categories have been identified using the computed ANS Index. Subjects with ANS index <11%, 11-20%, 21-50%, 51-60% and 61-100% were classified into healthy, early, late, advanced, and most-advanced diabetic cardiac autonomic neuropathy (DCAN) groups, respectively. We investigated prevalence of DCAN amongst well-controlled type-2 diabetes mellitus (T2DM) subjects within 1 year of diagnosis.

After obtaining informed consent, all T2DM subjects diagnosed within the past 12-months and hemoglobin A1C (A1C) ≤7 were included in the study. Eighteen of 29 subjects recruited were female, with a mean diabetes duration of 9-months and a mean A1C of 6.3% (5.3-7.0) [Table 1]. 10/29 subjects had no DCAN, whereas 4, 11, 1, and 3 subjects had early, late, advanced, and most-advanced DCAN, respectively.
Table 1: Diabetic cardiac autonomic neuropathy profile of 29 subjects with type 2 diabetes mellitus within one year of diagnosis and an A1C of <7.0

Click here to view

Our study clearly indicates that despite good glycemic control, almost two-third of recently diagnosed T2DM subjects in Pakistan have some level of DCAN. A similar study conducted in India demonstrated an even higher prevalence of DCAN, albeit using different diagnostic criteria. [4] It is a well-known fact that newly diagnosed T2DM subjects have the disease for at least 5-10 years before they are diagnosed. It is quite possible that if we diagnose diabetes earlier followed by aggressive treatment, we can prevent or reduce the morbidity associated with DCAN.

All our subjects had their diabetes under good control for at-least 3 months as indicated by an A1C<7.0. It seems that short-term good glycemic control does not reverse cardiac dysautonomia. Previous studies have shown that intensive diabetes control in type-1 diabetic subjects is associated with partial reversibility of DCAN. [5] Therefore, it would be interesting to compare the DCAN profile before and after good glycemic control.

American Diabetes Association recommends yearly screening for autonomic neuropathy in T2DM from the time of diagnosis. This cannot be accomplished efficiently unless there is a device available that is accurate and easy to use in a doctor's office setting. Portable ANSiscope seems to be a device that has the potential to meet all these needs of a busy diabetologist.

   References Top

1.Maser RE, Lenhard MJ. Cardiovascular autonomic neuropathy due to diabetes mellitus: Clinical manifestations, consequences, and treatment. J Clin Endocrinol Metab 2005;90:5896-903.  Back to cited text no. 1
2.Singh JP, Larson MG, O'Donnell CJ, Wilson PF, Tsuji H, Lloyd-Jones DM, et al. Association of hyperglycemia with reduced heart rate variability (The Framingham Heart Study). Am J Cardiol 2000;86:309-12.  Back to cited text no. 2
3.Bellavere F, Bosello G, Fedele D, Cardone C, Ferri M. Diagnosis and management of diabetic autonomic neuropathy. Br Med J (Clin Res Ed) 1983;287:61.  Back to cited text no. 3
4.Jyotsna VP, Sahoo A, Sreenivas V, Deepak KK. Prevalence and pattern of cardiac autonomic dysfunction in newly detected type 2 diabetes mellitus. Diabetes Res Clin Pract 2009;83:83-8.  Back to cited text no. 4
5.Burger AJ, Weinrauch LA, D'Elia JA, Aronson D. Effect of glycemic control on heart rate variability in type I diabetic patients with cardiac autonomic neuropathy. Am J Cardiol 1999;84:687-91.  Back to cited text no. 5


  [Table 1]

This article has been cited by
1 Cardiovascular autonomic neuropathy (CAN) in patients of type 2 diabetes mellitus: A tertiary care hospital based study
Zafar A. Arif,Imran Ali Shaikh,Naila Masood
Indian Heart Journal. 2014;
[Pubmed] | [DOI]


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  In this article
    Article Tables

 Article Access Statistics
    PDF Downloaded307    
    Comments [Add]    
    Cited by others 1    

Recommend this journal